Intervention not reported
Number suffering agitation as an adverse event · Alzheimer's disease (AD), moderate‐to‐severe
1 finding from 1 review
- no estimate extracted12 studies · 4395 participantsModerate
Findings
What do systematic reviews say?
1,310 questions · 1,358 findings · 214 reviews
No studies found 230 · 16.9%GRADE not reported 169 · 12.4%Very low 269 · 19.8%Low 277 · 20.4%Moderate 291 · 21.4%High 122 · 9%
Corticosteroid creams/ointments: clobetasol propionate foam vs vehicle foam
Primary: investigator‐rated good/excellent control of symptoms · participants with moderate to severe hand eczema
Corticosteroid creams/ointments: clobetasol propionate foam showed no clear difference in primary: investigator‐rated good/excellent control of symptoms compared with vehicle foam (moderate certainty).
1 finding from 1 review
- RR 1.43 [0.86, 2.4]1 study · 125 participantsModerate
Tacrolimus 0.1% vs mometasone furoate ointment
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Tacrolimus 0.1% vs mometasone furoate ointment
Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Tacrolimus 0.1% vs mometasone furoate ointment
Primary outcome 3: Adverse events · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
1 finding from 1 review
- no estimate extracted1 study · 16 participantsModerate
Tacrolimus 0.1% vs mometasone furoate ointment
Secondary: investigator‐rated reduction in severity ‐ DASIb · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
1 finding from 1 review
- no estimate extracted1 study · 16 participantsModerate
Tacrolimus 0.1% vs vehicle
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment probably leads to higher primary: investigator‐rated good/excellent control of symptoms compared with vehicle (moderate certainty).
1 finding from 1 review
- RR 29 [1.9, 443.25]1 study · 28 participantsModerate
Corticosteroid creams/ointments: clobetasol propionate foam vs vehicle foam
Primary: participant‐rated good/excellent control of symptoms · participants with moderate to severe hand eczema
Corticosteroid creams/ointments: clobetasol propionate foam probably leads to higher primary: participants with self‐rated good/excellent control of… compared with vehicle foam (moderate certainty).
1 finding from 1 review
- RR 2.32 [1.38, 3.91]1 study · 125 participantsModerate
Tacrolimus 0.1% vs vehicle
Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Tacrolimus 0.1% vs vehicle
Primary: adverse events ‐ burning/itching at application site · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment showed no clear difference in primary: adverse events ‐ burning/itching at application site compared with vehicle (moderate certainty).
1 finding from 1 review
- RR 9 [0.53, 152.93]1 study · 28 participantsModerate
Tacrolimus 0.1% vs vehicle
Secondary: investigator‐rated reduction in severity ‐ Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Oral retinoids: alitretinoin 30 mg vs placebo
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: investigator‐rated good/excellent control of symptoms compared with placebo (high certainty).
1 finding from 1 review
- RR 2.75 [2.2, 3.43]2 studies · 1210 participantsHigh
Oral retinoids: alitretinoin 30 mg vs placebo
Primary: participant‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: participant‐rated good/excellent control of symptoms… compared with placebo (high certainty).
1 finding from 1 review
- RR 2.75 [2.18, 3.48]2 studies · 1210 participantsHigh
Oral retinoids: alitretinoin 30 mg vs placebo
Adverse effects: headache · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: adverse events ‐ headache Folluw‐up: 48 weeks to 72 weeks compared with placebo (high certainty).
1 finding from 1 review
- RR 3.43 [2.45, 4.81]2 studies · 1210 participantsHigh
Corticosteroid creams/ointments: clobetasol propionate foam vs vehicle foam
Number of participants with any adverse event (primary tolerability outcome) · participants with moderate to severe hand eczema
Corticosteroid creams/ointments: clobetasol propionate foam showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with vehicle foam (moderate certainty).
1 finding from 1 review
- RR 2.24 [0.82, 6.06]1 study · 125 participantsModerate
Oral retinoids: alitretinoin 30 mg vs placebo
Secondary: investigator‐rated reduction in severity in TLSSc and mTLSSd · people with moderate to severe chronic hand eczema
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Oral retinoids: alitretinoin 10 mg vs placebo
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 10 mg leads to higher primary: investigator‐rated good/excellent control of symptoms compared with placebo (high certainty).
1 finding from 1 review
- RR 1.58 [1.2, 2.07]2 studies · 781 participantsHigh
Oral retinoids: alitretinoin 10 mg vs placebo
Primary: participant‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 10 mg leads to higher primary: participant‐rated good/excellent control of symptoms compared with placebo (high certainty).
1 finding from 1 review
- RR 1.73 [1.25, 2.4]2 studies · 765 participantsHigh
Oral retinoids: alitretinoin 10 mg vs placebo
Primary outcome 3: Adverse events · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 10 mg showed no clear difference in primary: all adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.01 [0.66, 1.55]1 study · 158 participantsModerate
Oral retinoids: alitretinoin 10 mg vs placebo
Secondary: investigator‐rated reduction in severity of TLSSd · people with moderate to severe chronic hand eczema
1 finding from 1 review
- no estimate extracted1 study · 158 participantsModerate